Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Locally Advanced Pancreatic Cancer 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1

Interventions

Gemcitabine 8Cystectomy 6Cisplatin 5Mitomycin 3toripalimab 2tislelizumab 2disitamab vedotin 2Radiotherapy 2Radiosurgery 2Magnetic Resonance Spectroscopy 2Drug Therapy 2zimberelimab 1trilaciclib 1sacituzumab govitecan 1nimotuzumab 1entinostat 1durvalumab 1cemiplimab 1Transurethral Resection of Bladder 1Therapeutics 1Synapsins 1Saline Solution 1Radiotherapy, Intensity-Modulated 1RC48 antibody 1Olive Oil 1Niacinamide 1Niacin 1Music Therapy 1Liquid Biopsy 1Immunonutrition Diet 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Urinary Bladder Neoplasms × zimberelimab × Clear all
NCT06528483 2024-07-30

preSAVE

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Not yet recruiting
63 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡